List of works - Maricla Galetti

5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line

scientific article

Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis

scientific article

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation

scientific article published on 19 March 2016

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

scientific article published on 12 December 2012

Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line

scientific article published on November 2004

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells

scientific article published on 21 July 2020

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

scientific article published on February 2008

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines

scientific article

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling

scientific article published on 21 August 2013

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

scientific article published on 22 December 2020

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer

scientific article published in October 2008

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer

scientific article published on January 2013

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

scientific article

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

scientific article (publication date: 2013)

Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens.

scientific article

Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI.

scientific article

Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion

scientific article

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

scientific article

Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial.

scientific article

Synergistic activity of letrozole and sorafenib on breast cancer cells

scientific article

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

List of works by Maricla Galetti

5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line

Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens.

Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI.

Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial.

Synergistic activity of letrozole and sorafenib on breast cancer cells

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC